Achieving composite endpoint of glycated haemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
To assess the effect of dulaglutide (DU) 1.5/0.75 mg in comparison with glimepiride (GLIM) or insulin glargine (GLAR) on the composite endpoint (CE) in Chinese type 2 diabetes (T2D) patients. Post-hoc analyses of 2 randomized phase III trials [NCT01644500 and NCT01648582] were performed using Fisher's exact test. Primary CE was the number of patients reaching glycated hemoglobin (HbA1c) less than 7.0%, without weight gain (WG), and hypoglycemia. Secondary composite endpoints included the number of patients reaching HbA1c less than 7.0% without WG and HbA1c less than 7.0% without hypoglycemia. Data of 1147 Chinese T2D patients were analyzed (NCT01644500=556; NCT01648582=591). In each analyzed trial, 40% - 48% of patients received DU (1.5 mg), 30% - 39% of patients received DU (0.75 mg), and 15% - 20% of patients on active comparators (GLIM/GLAR) reached primary composite endpoint at week 26 (P<0.001 for DU vs GLIM/GLAR). At 52 weeks, 26% of patients received DU (1.5 mg), 23% of patients received DU (0.75 mg), and 7% of patients received GLAR attained primary composite endpoint (P<0.001 for DU vs GLAR). A similar trend of results was found for secondary composite endpoints. Dulaglutide is found to be an effective therapeutic alternative for Chinese T2D patients. Compared to GLIM/GLAR, significantly greater proportions of patients on DU attained the HbA1c target of less than 7.0% without WG or hypoglycemia.